Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to test if taking a study drug called emricasan (also known
as IDN-6556 and PF-03491390) will affect overall patient survival after one month of
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)